guardant health

SoftBank’s Q1 2020 earnings presentation mixes comedy and drama

Hello and welcome back to our regular morning look at private companies, public markets and the gray space in between. Today we’re digging into SoftBank’s latest earnings slides. Not only

Karius raises $165 million for its liquid biopsy technology identifying diseases with a blood draw

“What Karius is good at is identifying those novel microbes before they become an outbreak like coronavirus,” says Mickey Kertesz, a chief executive whose life sciences startup just hauled

Xilis believes cultivating micro-tumors may hold the key to more effective cancer treatments

Despite near-miraculous advances in the treatment of cancer in the U.S. and around the world, the disease remains the second leading cause of death in America. The problem is that every manifestation

Pear, whose seed-stage bets are followed closely, just raised $160 million for its third fund

Pear, a six-year-old, Palo Alto, Calif.-based seed-stage firm whose bets on nascent startups are closely watched by early-stage investors, has closed on $160 million in capital commitments from a wide

At the sixth annual Pear Demo Day, weather balloons, branded credit cards and lots of top degrees

Pear, a Palo Alto-based seed-stage fund that has made its name through early bets on Guardant Health, DoorDash, Memebox and Gusto, hosted its sixth annual demo day this week in what proved to be a sco

A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing

This morning, a publicly traded transplant diagnostics company called CareDx, along with Stanford University, sued another publicly traded genetic testing company, Natera, for patent infringement. Muc

Guardant Health adds $360 million to its war chest

Guardant Health, a four-year-old, Redwood City, Ca.-based biotech company that sells blood tests to track and potentially detect cancer, has raised a whopping $360 million from investors, bringing its

Guardant Health, Which Tests for Cancer Through Blood Samples, Raises $100M In Series D Funding

Guardant Health, a three-year-old, Redwood Shores, Ca.-based company whose non-invasive genomic sequencing test for cancer requires just two vials of blood, has raised nearly $100 million in Series D

Guardant Health Secures $50 Million In Series C To Help More Doctors Track Cancer In Real Time

Guardant Health announced today that it has raised $50 million in Series C funding for its biopsy-free blood cancer screening test Guardant360. This puts the total funding for the medical technology s

Sequoia-Backed Guardant Health Wants To Improve Cancer Treatment And Diagnosis Via A New Blood Test

When testing for the possibility of certain types of cancer, doctors often do surgery to retrieve biopsies for genetic analysis. But when a patient has already had cancer, and is testing for a possibi